anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aim: To describe the epidemiological, clinical and laboratory characteristics and clinical progress of patients hospitalized with heart failure (HF) who started treatment with empagliflozin before discharge. Methods: We performed a retrospective observational study of patients aged ≥18 years admitted to the Internal Medicine Department of University Hospital Jaen, Jaen, Spain with acute HF between 1 May 2022 and 31 May 2023. Patients had to have a life expectancy of ≥1 year and have started treatment with empagliflozin during admission. Results: We included 112 patients (mean age, 85.2 ± 6.5 years; 67.9% women; 35.7 and 31.3% in NYHA functional classes III and IV; 73.2% with HF and preserved ejection fraction). Before admission, 80.4% were taking loop diuretics, 70.6% renin-angiotensin-aldosterone system inhibitors, 49.1% betablockers and 25% mineralocorticoid receptor antagonists. At admission, 94.6% were taking furosemide (15.2% at high doses, 36.6% at intermediate doses). The dose of furosemide was reduced at initiation of empagliflozin. At the end of follow-up, 13.4% of patients had died, 93.8% of the survivors continued treatment with empagliflozin and 26.8% had attended the emergency department with signs and symptoms of HF. Conclusion: Introduction of empagliflozin before discharge from hospital in patients admitted with HF made it possible to reduce the dose of diuretics during admission. The frequency of complications was as expected, and treatment was largely maintained.
A composition effective by oral administration in the treatment of treatable an mias comprises a mixure of dehydrated stomach tissue, dehydrated liver tissue, ascorbic acid, vitamin B12, folic acid and a therapeutically active ferrous salt, e.g. ferrous sulphate, ferrous gluconate or ferrous citrate, preferably in the anhydrous state.  The stomach tissue and liver tissue are those of the United States Pharmacopaeia XIV revision.  The dehydrated liver tissue material is preferably the dehydrated insoluble liver fraction of the said Pharmacopaeia. The composition is encapsulated to contain per capsule metallic iron 25 to 100 milligrams, vitamin B12 1 to 10 micrograms, folic acid 0.25-2.0 milligrams, ascorbic acid 25-100 milligrams, stomach tissue 75 to 200 milligrams and insoluble liver fraction 200 to 500 milligrams.  Examples relate to gelatin capsules containing 192 milligrams of exsiccated ferrous sulphate, 0.85 milligrams folic aid, 1 to 10 micrograms vitamin B12, 50 milligrams of ascorbic acid, 100 milligrams of stomach substance and 350 milligrams of insoluble liver fraction.
This will be a 28-day randomized controlled trial of the effects of a nutraceutical preparation on glycemic control in non-diabetic individuals with impaired glucose tolerance (IGT). IGT will be defined by American Diabetes Association criteria, as outlined in the list of inclusion and exclusion criteria (copy attached). There will be two active treatment arms and a placebo arm (3 arms total, n=12 completed subjects per arm). Following screening for inclusion/exclusion criteria and obtaining informed consent, subjects will be enrolled in the study and provided instructions to maintain their usual dietary pattern and physical activity level. If recent physical examination and medical history are not available; H\&P will be conducted and recorded for each enrolled subject. Subjects will be instructed to follow a 12-hour fast starting on day -1, and on the morning of day 0 fasting blood is drawn for analyses indicated below and the supplements are distributed. Supplements are distributed using a blinding protocol and a variable, known pill allotment in order to assess compliance via standard pill counts. Pill bottles and all unused supplements are returned at seven day intervals, with new supplies being distributed at that time. Fasting blood samples are obtained on days 0, 7, 14 and 28. Samples from each day are analyzed for glucose and insulin. Samples from days 0, 14 and 28 are also analyzed for fructosamine, C-peptide, glucagon and F2-isoprostanes. A75 g oral glucose tolerance test administered on days 0 and 28.
A complex microbial preparation comprises (in vol. %):  Photosynthetic bacterium  (5-15%),  Bacillus  (10-20%), Yeasts (20-35%),  Lactobacillus  (30-45%) and  Actinomycetes  (3-10%). The preparative method of the complex microbial preparation involves first and second level complex fermentations. The first level complex fermentation involves: (a) separately inoculating the above-mentioned bacteria on first level culture media and culturing to obtain first level bacteria, (b) separately inoculating the obtained first level bacteria on second level culture media and culturing to obtain fermenting bacterial liquids, (c) mixing the five obtained fermenting bacterial liquids to obtain first level compound bacteria. The second level complex fermentation involves: adding sterile water,  Lactobacillus plantarum ,  Lactobacillus acidophilus ,  Saccharomyces cerevisiae  and brown sugar to the obtained first level compound bacteria, mixing uniformly in a same fermentor, and culturing to obtain second level complex microbial preparation. The complex microbial preparation is used in treatment for diabetes.
Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
Three novel low molecular weight (LMW) polypeptide fragments of a proteolipid protein human PLP/DM20 are designated PIRP-M, PIRP-L and PIRP-J, and are growth factors for oligodendrocytes with anti-apoptotic activity. They are encoded by mRNA from an IRES. Fusion polypeptides of such a LMW polypeptide, DNA encoding the LMW polypeptide and fusion polypeptide, expression vectors comprising such DNA, and cells expressing such polypeptides, or pharmaceutical compositions thereof, are useful for stimulating neural stem cell differentiation, maturation along the oligodendrocytic pathway and proliferation of oligodendrocytes or precursors. These compositions can protect oligodendrocytes (and nonneural cells) from apoptotic death. Thus, the present composition is used to treat a disease or condition in which such differentiation, maturation and proliferation or inhibition of cell death, including remyelination or stimulation of oligodendroglia or Schwann cells, is desirable. Disorders include multiple sclerosis, trauma with Parkinson's-like symptoms, hypoxic ischerriia and spinal cord trauma.
The following safety features should be present: (1) Protection from electrical hazard: All units should be grounded and conform to applicable electrical codes. The patient or operator should not be able to touch any live electrical parts. There should be ground fault protection. (2) Protective shielding of lamps: The patient should not be able to come in contact with the bare lamps. In the event of lamp breakage, the patient should not be exposed to broken lamp components. (3) Hand rails and hand holds: Appropriate supports should be available to the patient. (4) Patient viewing window: A window which blocks UV should be provided for viewing the patient during treatment. (5) Door and latches: Patients should be able to open the door from the inside with only slight pressure to the door. (6) Non-skid floor: The floor should be of a non-skid nature. (7) Thermoregulation: Sufficient air flow should be provided for patient safety and comfort, limiting temperature within the UVA radiator cabinet to approximately less than 100 °F. (8) Timer: The irradiator should be equipped with an automatic timer which terminates the exposure at the conclusion of a pre-set time interval. (9) Patient alarm device: An alarm device within the UVA irradiator chamber should be accessible to the patient for emergency activation. (10) Danger label: The unit should have a label prominently displayed which reads as follows:

DANGER - Ultraviolet radiation - Follow your physicians instructions - Failure to use protective eyewear may result in eye injury.
The method shall be applied for the prevention and treatment of diarrhoeas, gastrointestinal infections and dysbacteriosis in humans and animals, as well as for the cholesterol level regulation and for reinforcing the immune system. The freeze-dry and standardized products are administered as preparations for direct application and as yeasts for the preparation of fermented lactic acid products of probiotic effect. By the method probiotics are produced having high titre of live active cells of mixed and symbiotic cultures of selected strains of LAB 8 lactobacilli and streptococci, registered in NBIMCC under No. 2416, Lactobacillus LBC 7, registered in NBIMCC under No, 3599, Lactobacillus LBG-MZ, registered in NBIMCC under No. 3600, Lactobacillus bulgaricus LB 51-157, registered in NBIMCC under No. 3598, Streptococcus thermophilus 35, registered in NBIMCC under no. 3597 and Bifidobacterium bifidum BB 87, registered in NBIMCC under No. 3601. 1 claim
PROBLEM TO BE SOLVED: To obtain the subject premenstrual syndrome depressant composition that is effective for inhibiting the symptoms developing as premenstrual syndrome by admixing theanine as an active ingredient thereto. SOLUTION: The objective composition is prepared by using theanine as an active ingredient. The theanine is a glutamic acid derivative distributing in tea leaves, one of the main flavor enhancer for tea and has been used as a food additive for flavoring. The theanine is obtained by extraction from tea leaves, via an organic synthetic route or action of glutaminase on the mixture of glutamic acid and ethylamine. The tea leaves are, for example, leaves of green tea, oolong tea, black tea or the like. L-form is preferably used as the theanine. The daily dose of the theanine is 0.2-200 mg/kg of body weight, preferably 0.5-50 mg/kg of body weight.
One group will include 20 women under the age 40 years old, with regular menstruation cycles and without any illness or medication including birth control pills or steroidal ointments, and without known diagnosis of polycystic ovaries or fertility disorder. The second group will include 20 women over the age of 60, with no menstruation at least for the last five years, and without hormone therapy or treatment of any Steroidal therapy for the last year.

From all of the participants the investigators will collect hair samples at the crown back of the head (hair will be cut as close as possible to the scalp), the samples will be measured quantitatively about 100 hairs at a length of 2-3 cm. In order to grind the hair samples we will use a mini-Bead beater machine. milled hairs will be incubated overnight in a solution of 1 ml methanol 50, in constant gentle muddling. Afterwards, ethanol will disperse through a stream of nitrogen. The remainder of the suspension will be dissolved at 200 microliter buffer PBS (Phosphate-Buffered Saline) (pH 8.0) and the concentration of estrogen and progesterone will be measured by using the immune method which is available in the endocrine laboratory in Bnai Zion medical center. At the end of the study the investigators will cary out a statistical comparison of progesterone and estrogen levels between the two groups.
INTRODUCTION AND HYPOTHESIS: The objective was to investigate the incidence and risk factors of lower extremity deep vein thrombosis (DVT) in elderly women undergoing colpocleisis for pelvic organ prolapse and to evaluate the predictive efficacy of the Caprini scores.
METHODS: Data from patients who underwent colpocleisis from August 2019 to April 2024 were retrospectively analyzed. The primary endpoint was DVT detected by ultrasonography within 7 days of surgery. Univariate and multivariate logistic regression analyses were applied to identify independent risk factors. Efficacy parameters of the Caprini scores were analyzed and optimal cut-off values were selected.
RESULTS: A total of 262 patients were enrolled in the study, of whom 8.4% (22 out of 262) developed DVT postoperatively. After statistical analysis, the duration of menopause, history of inflammatory bowel disease, as well as higher levels of preoperative cholesterol and preoperative D-dimer, were identified as independent risk factors. There was a significant difference in the Caprini scores between the DVT and non-DVT groups (7.27 ± 1.28 vs 6.15 ± 0.80, p < 0.001), and the risk of DVT tended to increase with higher Caprini scores. The best performance was achieved when the threshold for the Caprini score was set to 7, at which point the area under the receiver operating characteristic curve was 0.758, the sensitivity was 0.773, and the specificity was 0.662.
CONCLUSION: There was a strong correlation between the occurrence of DVT after colpocleisis and the Caprini score, with higher Caprini scores indicating a higher risk of postoperative DVT. A significantly increased risk was suggested when this score was ≥ 7.
BACKGROUND: Long non-coding RNAs (LncRNA) play a pivotal role in the progression of various malignancies. Despite recent identification as an oncogene associated with tumorigenesis. The precise role of LINC01605 in cervical cancer (CC) remains unclear. Therefore, the objective of this study was to investigate the influence of LINC01605 on proliferation and invasion of CC cells, while also exploring its potential underlying mechanisms.
METHODS: The expression of LINC01605 in CC cell lines was analyzed using the TCGA database and qRT-PCR. Various assays, including CCK-8 and transwell analysis, were conducted on CC cells to assess the influence of LINC01605 on their proliferation, migration, and invasion capabilities. Bioinformatics and dual luciferase reporter gene assays were employed to analyze the target genes of LINC01605 and miR-149-3p. To further investigate the mechanism of action, transfection and investigation were performed using specific siRNA, miRNA mimics, or inhibitors.
RESULTS: The expression of LINC01605 exhibited a significant increase in CC cell lines, and this upregulation was associated with an unfavorable prognosis. Modulating the expression of LINC01605, either by down-regulating or up-regulating it, exerted suppressive or stimulatory effects on the growth and invasion of HeLa and Siha cells. LINC01605 functioned as a competitive endogenous RNA (ceRNA) for miR-149-3p, with WNT7B being identified as a target gene of miR-149-3p. The involvement of LINC01605 in CC development is facilitated by its ability to regulate the expression of WNT7B through sequestering miR-149-3p.
CONCLUSION: Our study demonstrates that LINC01605 acts as a competitive endogenous RNA in modulating the effects of WNT7B on the proliferation and invasion of CC cells by sequestering miR-149-3p. This research provides novel insights into the involvement of LINC01605 in the advancement of CC.
Patients treated intravenously receives a bolus of DEX (2 mcg/kg over ten minutes), followed by continuous infusion (1-2 mcg/kg/hour), stopped at the end of the procedure. The bolus could be repeated up to three times to reach the optimal target level of sedation before starting the continuous infusion.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention concerns veterinary medicine, namely to agents prepared from medical plants. The invention consists in the following. Mixture of the following medical plants crushed to fine and ultrafine particles and treated with bactericidal lamps rays are placed in a sterile tank of dark glass: dry stalks, leaves and flowers of peppermint, dry flowers of wild chamomile, dry leaves of waybread and dry flower heads of costmary (Tanacetum vulgare), dry stalks, leaves and flowers of yellow melilot, dry grass of St. John's wort, dry flowers of pot marigold, dy grass of milfoil, dy grass of thyme, dry stalks, leaves, flowers and fruits of celandine, dry leaves of eucalyptus, dry leaves and flower heads of coltsfoot, dry leaves of garden sage, dry leaves of stinging nettle, dry grass of common persicaria, dry flowers of densely flowered mullein, bark of ordinary oak, roots of common licoric, ground fruits of anise and rose hips, walnut kernel, buckthorn pulp without kernels, their fruits and berries. These components are treated with bactericidal lamps rays and crushed to fine and ultrafine particles, then placed to a tank of dark glass, mixed with sterile cooking salt solution with 0.9% sodium content, and with formalin. The mixture is left and room temperature for 3-4 days, regularly stirred, and then placed to water bath for 10-12 hours and exposed to temperature up to 40, with contiuous stirring. After that the liquid part is separated from the vegetable sediment. The tincture is stored in tanks of dark glass or in a darkened room at a temperature of 2-4C, and is applied externally and internally, and the vegetable sediment is used as fodder and remedy for animals and birds, especially for chickens in case of cannibalism. ^ EFFECT: at experimental checks of therapeutic efficacy of the agent, good results were achieved in prevention and treatment of inflammatory processes among animals; wide application in veterinary. ^ 3 cl
Chronic Kidney Disease (CKD) has emerged as a global public health concern, with its primary pathological basis being Renal Fibrosis (RF), crucial to halt its progression to End-Stage Renal Disease (ESRD). However, effective treatment options are currently lacking. Therefore, exploring the mechanisms of RF, identifying drug targets and diagnostic biomarkers are important. In this study, we identified ADAMTS16 as a newly expressed regulatory factor highly expressed in renal fibrosis tissue. ADAMTS16 interacts with latency-associated peptide (LAP)-transforming growth factor (TGF)-β, leading to the activation of TGF-β. Loss of ADAMTS16 expression effectively reduces TGF-β-dependent transcription activity. Furthermore, the use of RRFR tetrapeptide derived from ADAMTS16 can activate the TGF-β/Smad signaling axis, promoting RF. In summary, ADAMTS16 is induced in the progression of CKD, interacting with LAP-TGF-β and potentially activating SMAD2/3. Therefore, targeting ADAMTS16 may serve as a crucial new strategy to alleviate RF and treat CKD patients.
How Supplied

ILUMYA (tildrakizumab-asmn) Injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. ILUMYA is supplied as one single-dose prefilled syringe per carton that delivers 1 mL of a 100 mg/mL solution. 

  * NDC 47335-177-95



Each prefilled syringe is equipped with a passive needle guard and a needle cover.

Storage and Handling

Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until the time of use. Do not freeze. Do not shake. ILUMYA can be kept at room temperature at 25°C (77°F) for up to 30 days in the original carton to protect from light. Once stored at room temperature, do not place back in the refrigerator. If not used within 30 days, discard ILUMYA. Do not store ILUMYA above 25°C (77°F).
PURPOSE OF REVIEW: In the decade since the first publications related to frailty in those with critical illness, the study of frailty has rapidly increased. The purpose of this review is to update the reader on recent advances across several important areas of frailty research: how best to identify frailty in those with critical illness, studies describing the relationship between frailty and delirium, and how frailty affects outcomes for those with coronavirus disease 2019 (COVID-19), which, despite rates and severity of acute infection declining, still tremendously impacts patients long after the acute infection, resulting in symptoms of long COVID-19.
RECENT FINDINGS: A number of frailty assessment tools exist, to date, the Clinical Frailty Scale based on the deficit accumulation approach to defining frailty, is the most commonly used in ICU studies. Several novel frailty instruments for the ICU are being developed. Because tools assessing frailty by the phenotypic and deficit accumulation approaches identify different populations, careful choice of a frailty assessment tool is warranted.Frailty and delirium are hypothesized to represent different clinical expressions of a similar underlying vulnerability, thus identifying frailty may be a useful means by which to identify patients at high risk of becoming delirious. Recent studies show that frailty at ICU admission is a predictor of the development of delirium.Finally, frailty and its outcomes were studied in patients with COVID-19. As with other causes of critical illness, frailty was highly prevalent in those admitted to the ICU and is associated with greater mortality. Frailty was also associated with increased decisions to limit life support treatments, but these decisions were not different among those admitted with COVID-19 or for other reasons.
SUMMARY: Frailty in those with critical illness is an emerging field of study. Future work to define the optimal means by which to identify this syndrome and how best to manage critically ill patients with frailty are needed.
OBJECTIVE: The purpose of this protocol is to study the natural history of Fabry disease in the different organ systems, understand its pathogenesis, and develop adequate clinical outcome measures for therapy trials. Development of sensitive outcome measures is a prerequisite of enzyme or gene replacement trials in patients with Fabry's disease. STUDY POPULATION: Patients with Fabry disease of all ages. The patients are not foregoing available treatment to participate in this protocol. Experimental treatment is not part of this study. STUDY DESIGN: Patients will typically be seen once a year at NIH. Patients will have comprehensive testing in order to evaluate the state of their health as affected by the Fabry disease. OUTCOME MEASURES: All potential clinically relevant areas will be evaluated comprehensively with a particular emphasis on the vasculopathy and the peripheral neuropathy of Fabry disease.
Participants with ST (except for HCC) will receive E7386, BID for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386, BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
The invention discloses fig wine and a preparing method thereof. The fig wine is prepared from steeping medicinal liquor, a fig wine base, alcohol, citric acid, white sugar, ethyl acetate, ethyl lactate, caramel color and purified water. The fig wine contains medicinal liquor and can purify blood, improve the breathing function, promote metabolism, regulate internal secretion, relieve tension and the like. The fig wine contains fig wine base which has rich nutrients, and figs are mild and sweet, can invigorate stomach, clear intestines and achieve detumescence and detoxication, and can be used for treating enteritis, dysentery, astriction, haemorrhoids, laryngalgia, ulcerative carbuncle, scabies and the like. The wine base made from figs has higher nutritive value and better effect. By adding citric acid, white sugar, ethyl acetate, ethyl lactate and caramel color, the taste of the fig wine is improved, and the nutritive value is increased.